A newly identified "blood signature" may predict lung cancer risk more than five years before diagnosis, offering a potential pathway to earlier prevention, a study has revealed. 

The findings, published in Cell, could help identify people who would benefit from preventative drugs, even before they receive a lung cancer diagnosis, said a statement from Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) released Friday.